Format

Send to

Choose Destination
JAMA Dermatol. 2019 Apr 1;155(4):503-504. doi: 10.1001/jamadermatol.2018.4990.

Restrictive FDA Requirements and the Development of Generic Topical Medications-Reply.

Author information

1
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2
Tufts University School of Medicine, Boston, Massachusetts.
PMID:
30810704
DOI:
10.1001/jamadermatol.2018.4990
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center